Incyte Corporation Company Profile (NASDAQ:INCY)

About Incyte Corporation (NASDAQ:INCY)

Incyte Corporation logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INCY
  • CUSIP: 45337C10
  • Web:
  • Market Cap: $28.09 billion
  • Outstanding Shares: 204,774,000
Average Prices:
  • 50 Day Moving Avg: $127.92
  • 200 Day Moving Avg: $128.27
  • 52 Week Range: $75.52 - $153.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 274.38
  • P/E Growth: -8.39
Sales & Book Value:
  • Annual Revenue: $1.23 billion
  • Price / Sales: 22.84
  • Book Value: $4.72 per share
  • Price / Book: 29.07
  • EBIDTA: $35.53 million
  • Net Margins: -8.72%
  • Return on Equity: -20.09%
  • Return on Assets: -6.64%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 2.69%
  • Quick Ratio: 2.68%
  • Average Volume: 1.71 million shs.
  • Beta: 0.85
  • Short Ratio: 1.76
Frequently Asked Questions for Incyte Corporation (NASDAQ:INCY)

What is Incyte Corporation's stock symbol?

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte Corporation's earnings last quarter?

Incyte Corporation (NASDAQ:INCY) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The firm had revenue of $384.08 million for the quarter, compared to analyst estimates of $359.19 million. Incyte Corporation had a negative net margin of 8.72% and a negative return on equity of 20.09%. The business's quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.12 earnings per share. View Incyte Corporation's Earnings History.

Where is Incyte Corporation's stock going? Where will Incyte Corporation's stock price be in 2017?

21 brokerages have issued twelve-month target prices for Incyte Corporation's shares. Their forecasts range from $98.00 to $185.00. On average, they anticipate Incyte Corporation's share price to reach $143.53 in the next twelve months. View Analyst Ratings for Incyte Corporation.

What are analysts saying about Incyte Corporation stock?

Here are some recent quotes from research analysts about Incyte Corporation stock:

  • 1. Cowen and Company analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
  • 2. According to Zacks Investment Research, "Incyte’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations. The growth in Jakafi sales is driven by patient demand and should boost revenues. While most of the demand is due to a larger established patient base in myelofibrosis, polycythemia vera is also expected to be a major long-term driver of Jakafi growth. This is owing to the larger potential patient population and the possibility for longer duration of treatment. The company exited the first quarter with approximately 10,000 patients being treated with Jakafi. However, Incyte’s dependence on a single product, Jakafi, for growth is concerning. Moreover, the FDA has issued a CRL to new drug application (NDA) for baricitinib asking for additional information. The delay in approval is disappointing. Moreover, loss estimates for 2017 have widened significantly following the first-quarter results." (5/23/2017)
  • 3. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)

Are investors shorting Incyte Corporation?

Incyte Corporation saw a decrease in short interest in June. As of June 15th, there was short interest totalling 3,023,910 shares, a decrease of 27.7% from the May 31st total of 4,182,735 shares. Based on an average daily volume of 1,929,555 shares, the short-interest ratio is currently 1.6 days. Approximately 1.5% of the shares of the stock are sold short.

Who are some of Incyte Corporation's key competitors?

Who are Incyte Corporation's key executives?

Incyte Corporation's management team includes the folowing people:

  • Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer
  • David W. Gryska, Chief Financial Officer, Executive Vice President
  • Reid M. Huber, Executive Vice President, Chief Scientific Officer
  • Eric H. Siegel, Executive Vice President, General Counsel
  • Paula J. Swain, Executive Vice President - Human Resources
  • Barry P. Flannelly, Executive Vice President and General Manager , US
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development`
  • Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry
  • Steven H. Stein M.D., Vice President and Chief Medical Officer
  • Julian C. Baker, Lead Independent Director

Who owns Incyte Corporation stock?

Incyte Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include BAKER BROS. ADVISORS LP (16.80%), Boston Advisors LLC (0.08%), National Pension Service (0.07%), Chevy Chase Trust Holdings Inc. (0.07%), Strs Ohio (0.05%) and Bank of Montreal Can (0.04%). Company insiders that own Incyte Corporation stock include Barry P Flannelly, David W Gryska, Eric H Siegel, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy, Steven H Stein and Yao Wenqing. View Institutional Ownership Trends for Incyte Corporation.

Who sold Incyte Corporation stock? Who is selling Incyte Corporation stock?

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Bank of Montreal Can, Russell Investments Group Ltd., Exxonmobil Investment Management Inc. TX, Chevy Chase Trust Holdings Inc., Nisa Investment Advisors LLC, Hartford Investment Management Co. and Rockefeller Financial Services Inc.. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte Corporation.

Who bought Incyte Corporation stock? Who is buying Incyte Corporation stock?

Incyte Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, First American Trust FSB, Mn Services Vermogensbeheer B.V., National Pension Service, Oregon Public Employees Retirement Fund, ING Groep NV, Oakbrook Investments LLC and Sit Investment Associates Inc.. Company insiders that have bought Incyte Corporation stock in the last two years include Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte Corporation.

How do I buy Incyte Corporation stock?

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte Corporation's stock price today?

One share of Incyte Corporation stock can currently be purchased for approximately $137.19.

MarketBeat Community Rating for Incyte Corporation (NASDAQ INCY)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  774 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  988
MarketBeat's community ratings are surveys of what our community members think about Incyte Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Incyte Corporation (NASDAQ:INCY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $143.53 (4.62% upside)

Analysts' Ratings History for Incyte Corporation (NASDAQ:INCY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017BMO Capital MarketsReiterated RatingBuy$172.00HighView Rating Details
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00LowView Rating Details
7/4/2017Jefferies Group LLCReiterated RatingBuy$165.00MediumView Rating Details
7/4/2017Barclays PLCBoost Price TargetOverweight$135.00 -> $185.00MediumView Rating Details
7/3/2017Cowen and CompanyReiterated RatingOutperform$130.00MediumView Rating Details
6/28/2017GabelliReiterated RatingBuy$174.00MediumView Rating Details
6/6/2017Oppenheimer Holdings, Inc.Set Price TargetHold$135.00LowView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
5/18/2017J P Morgan Chase & CoSet Price TargetBuy$149.00MediumView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
4/19/2017SunTrust Banks, Inc.Lower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/18/2017Goldman Sachs Group, Inc. (The)Lower Price TargetBuy$149.00 -> $136.00LowView Rating Details
4/17/2017Raymond James Financial, Inc.Reiterated RatingHoldHighView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
4/4/2017Royal Bank Of CanadaBoost Price TargetOutperform$138.00 -> $157.00LowView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
9/26/2016ArgusBoost Price TargetBuy$92.00 -> $98.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of America CorporationReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Incyte Corporation (NASDAQ:INCY)
Earnings by Quarter for Incyte Corporation (NASDAQ:INCY)
Earnings History by Quarter for Incyte Corporation (NASDAQ INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte Corporation (NASDAQ:INCY)
2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.01)($0.82)($0.93)
Q2 20175($0.08)$0.61$0.28
Q3 20175($0.08)$0.44$0.19
Q4 20175($0.06)$0.27$0.12
(Data provided by Zacks Investment Research)


Dividend History for Incyte Corporation (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Incyte Corporation (NASDAQ:INCY)
Insider Ownership Percentage: 17.70%
Institutional Ownership Percentage: 92.40%
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2017Steven H SteinEVPSell6,485$131.09$850,118.65View SEC Filing  
7/5/2017Paul TrowerInsiderSell3,000$126.18$378,540.00View SEC Filing  
7/3/2017Eric H SiegelEVPSell1,820$126.20$229,684.00View SEC Filing  
6/30/2017David W GryskaInsiderSell599$129.74$77,714.26View SEC Filing  
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.00View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.60View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.00View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.00View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.00View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.00View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.17View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.60View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.00View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.00View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.00View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.74View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.00View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.00View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Incyte Corporation (NASDAQ:INCY)
Latest Headlines for Incyte Corporation (NASDAQ:INCY)
DateHeadline logoBRIEF-Lilly and Incyte provide update on baricitinib - July 26 at 1:17 AM logoLilly and Incyte Provide Update on Baricitinib - PR Newswire (press release) - July 25 at 8:09 PM logoIncyte Corporation (NASDAQ:INCY) Given "Buy" Rating at BMO Capital Markets - July 22 at 11:34 AM logoIncyte Corporation (NASDAQ:INCY) EVP Steven H. Stein Sells 6,485 Shares - July 21 at 4:28 PM logo2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't - July 21 at 3:43 PM logoAEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK - July 21 at 4:49 AM logoIncyte launches late-stage study assessing JAK1 inhibitor itacitinib in in GvHD - July 20 at 10:03 AM logoIncyte Co. (INCY) PT Set at $152.00 by Credit Suisse Group - July 17 at 11:42 PM logoIncyte Corporation (INCY) to Post FY2019 Earnings of $1.87 Per Share, Leerink Swann Forecasts - July 17 at 11:28 AM logoResearch Analysts Set Expectations for Incyte Corporation's Q4 2017 Earnings (INCY) - July 17 at 10:48 AM logo$316.11 Million in Sales Expected for Incyte Corporation (INCY) This Quarter - July 15 at 8:07 AM logoLeerink's Porges says Incyte good target for Gilead - July 14 at 11:55 AM logo Brokerages Expect Incyte Corporation (NASDAQ:INCY) Will Announce Earnings of -$0.05 Per Share - July 13 at 6:30 PM logoInsider Selling: Incyte Corporation (INCY) Insider Sells 3,000 Shares of Stock - July 7 at 8:16 PM logoIncyte Corporation (NASDAQ:INCY) Expected to Earn FY2017 Earnings of ($0.55) Per Share - July 7 at 11:18 AM logoIncyte Corporation (INCY) Lowered to Hold at BidaskClub - July 6 at 11:28 PM logoQ3 2017 Earnings Forecast for Incyte Corporation (INCY) Issued By Oppenheimer Holdings - July 6 at 8:00 AM logoDavid W. Gryska Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock - July 5 at 7:44 PM logoIncyte Corporation (NASDAQ:INCY) EVP Eric H. Siegel Sells 1,820 Shares - July 5 at 7:26 PM logoIncyte Corporation (NASDAQ:INCY) PT Raised to $185.00 - July 4 at 10:58 PM logoIncyte Corporation (INCY) Receives "Buy" Rating from Jefferies Group LLC - July 4 at 10:58 PM logoIncyte Corporation (INCY) Rating Reiterated by Cowen and Company - July 3 at 8:56 PM logoEli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts - July 3 at 7:23 PM logoIncyte Corporation (INCY) Given Consensus Rating of "Buy" by Analysts - July 3 at 12:40 PM logoGabelli Reaffirms "Buy" Rating for Incyte Corporation (INCY) - July 2 at 1:20 PM logoFriday Sector Laggards: Financial, Healthcare - Nasdaq - June 30 at 8:02 PM logoIncyte Corporation (INCY) Sees Significant Decrease in Short Interest - June 29 at 7:14 AM logoIncyte Corporation (INCY) EVP Sells $1,235,375.00 in Stock - June 22 at 7:28 PM logoSmall Cancer Biotech Space in Focus, 3 Stocks Up 100% & More - June 21 at 3:36 PM logo4 Stocks & ETFs to Buy on Clovis' Positive Drug Data - June 21 at 3:36 PM logoIncyte Corporation (INCY) Receives Buy Rating from Jefferies Group LLC - June 20 at 1:40 PM logoZacks: Analysts Expect Incyte Corporation (INCY) Will Announce Earnings of -$0.04 Per Share - June 19 at 6:46 PM logoIncyte Corporation Expected to Post Q4 2017 Earnings of $0.18 Per Share (INCY) - June 19 at 7:21 AM logoIncyte (INCY) Presents At The William Blair 2017 Growth Stock Conference - Slideshow - June 16 at 5:25 AM logoHow Did Incyte’s Product Portfolio Look in 1Q17? - June 16 at 5:25 AM logoHow Incyte’s Jakafi Performed in 1Q17 - June 16 at 5:25 AM logoNew Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 - June 16 at 5:25 AM logoInsider Selling: Incyte Corporation (INCY) CFO Sells 16,756 Shares of Stock - June 14 at 10:31 PM logoIncyte Corporation (INCY) Given Buy Rating at Credit Suisse Group - June 11 at 11:32 PM logoIncyte (INCY) Up 3.4% Since Earnings Report: Can It Continue? - Nasdaq - June 11 at 11:11 PM logoIncyte Co. (INCY) Earns "Overweight" Rating from Barclays PLC - June 11 at 12:46 PM logoCORRECTED-UPDATE 3-AbbVie's rheumatoid arthritis drug succeeds in trial - June 7 at 11:31 PM logoInsider Selling: Incyte Co. (INCY) Insider Sells 3,000 Shares of Stock - June 7 at 7:50 PM logoAbbVie's rheumatoid arthritis drug succeeds in trial - June 7 at 5:30 PM logoIncyte Co. (INCY) Given a $135.00 Price Target at Oppenheimer Holdings Inc. - June 7 at 4:50 PM logoUPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage trial - June 7 at 10:05 AM logoSolid Progress For IDO Inhibitors - June 7 at 10:05 AM logoIncyte Co. (INCY) Given Consensus Rating of "Buy" by Brokerages - June 6 at 12:52 PM logoBMO Capital Markets Reiterates Outperform Rating for Incyte Co. (INCY) - June 5 at 10:00 PM logoCowen and Company Reiterates Buy Rating for Incyte Co. (INCY) - June 5 at 9:22 PM



Incyte Corporation (INCY) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff